Mineralys Therapeutics, Inc. Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: As of December 31, 2025, the company reported cash, cash equivalents, and investments of $656.6 million, a significant increase from $198.2 million at the end of 2024. This is expected to fund operations into 2028.

R&D Expenses: For the year, R&D expenses totaled $132 million, down from $168.6 million in 2024. Q4 R&D expenses were $24.4 million, compared to $44.6 million in Q4 2024, primarily due to the conclusion of lorundrostat’s pivotal program.

G&A Expenses: General and administrative expenses rose to $38.6 million for the year, up from $23.8 million in 2024, driven by increased compensation and professional fees.

Net Loss: The net loss for 2025 was $154.7 million, an improvement from $177.8 million in 2024. The Q4 net loss was $32.2 million, down from $48.9 million in Q4 2024.

2Strategic Updates and Business Highlights

NDA Acceptance: The FDA accepted the New Drug Application (NDA) for lorundrostat, targeting hypertension treatment, with a PDUFA date set for December 22, 2026.

Clinical Trials: Five positive clinical trials were completed, demonstrating significant blood pressure reduction and safety. The EXPLORER-OSA trial showed blood pressure reductions, although it did not meet its primary endpoint related to obstructive sleep apnea (OSA).

Market Preparation: The company is actively engaging with payers and planning for market access to support the upcoming launch of lorundrostat. They are expanding their medical communications and field-based teams to enhance data dissemination.

3Forward Guidance and Outlook

Clinical Development: The company aims to explore further indications for lorundrostat, particularly in comorbid conditions associated with hypertension.

R&D Spending: A reduction in R&D expenses is expected in 2026 compared to 2025, as fewer trials are ongoing.

Commercial Strategy: The company is preparing for a potential launch and is evaluating its commercial capabilities, including hiring and market strategies.

4Bad News, Challenges, or Points of Concern

Competitive Pressure: AstraZeneca is expected to launch a competing product in the second quarter of 2026, which may impact lorundrostat's market entry strategy.

Clinical Trial Limitations: The EXPLORER-OSA trial did not achieve its primary endpoint, raising questions about the design and its implications for future studies.

Market Access Risks: Although initial payer interactions are positive, there are uncertainties regarding coverage and pricing strategies, especially in a competitive landscape.

5Notable Q&A Insights

Commercial Strategy: The CEO emphasized the importance of understanding competitor pricing and market strategies to optimize lorundrostat's launch.

Payer Engagement: The company is optimistic about payer access, particularly for third-line treatments, and is actively scheduling pre-approval discussions with payers.

Future Indications: There is potential for lorundrostat to be explored in various comorbid conditions, with a focus on being a first-in-class treatment rather than following competitors.

Partnership Opportunities: The company is open to partnerships that align with its vision for lorundrostat, particularly in expanding its market presence and addressing complex patient needs. This summary encapsulates the key aspects of Mineralys Therapeutics' Q4 2025 earnings call, highlighting financial performance, strategic initiatives, and market outlook while addressing potential challenges and competitive dynamics.